Tissue Repair Ltd (AU:TRP)
ASX:TRP
TRP Stock Chart & Stats
AU$0.38
AU$0.02(5.56%)
At close: 4:00 PM EST
AU$0.38
AU$0.02(5.56%)
Day’s Range― - ―
52-Week RangeAU$0.15 - AU$0.48
Previous CloseN/A
Volume13.59K
Average Volume (3M)93.72K
Market Cap
AU$9.07M
Enterprise ValueAU$775.26K
Total Cash (Recent Filing)AU$12.32M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding60,464,844
10 Day Avg. Volume171,402
30 Day Avg. Volume93,720
Financial Highlights & Ratios
PEG Ratio-1.06
Price to Book (P/B)0.80
Price to Sales (P/S)4.25
P/FCF Ratio-2.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Acceleration & MarginsA sharp revenue jump in 2025 alongside very high gross margins indicates meaningful commercial traction for core products or services. Sustained top-line momentum and strong unit economics improve the probability of reaching break-even as the company scales, supporting durable revenue conversion and investment ROI.
Debt-Free Balance SheetZero debt materially reduces financial and refinancing risk for a clinical-stage biotech, preserving capacity to raise equity on favorable terms and allocate cash to R&D. Absence of interest expense supports operational flexibility and lowers fixed obligations during long clinical development timelines.
Cash Losses Track Reported LossesFree cash flow closely tracking net losses implies reported deficits reflect real cash burn rather than accounting non-cash charges. This improves forecasting reliability and transparency, allowing management and investors to plan financing and capital allocation with clearer visibility on true runway needs.
Bears Say
Persistent UnprofitabilitySustained operating losses and significant negative free cash flow show the business is still in heavy investment mode with no near-term profitability. Over time this raises funding dependency, increases dilution risk from future capital raises, and constrains the firm’s ability to self-fund clinical programs.
Eroding Shareholders' EquityA multi-year decline in equity reflects accumulated deficits and value erosion, weakening the balance sheet buffer contractors and partners rely on. Lower book equity reduces financial resilience, heightens the need for external funding, and can impair negotiating leverage for strategic partnerships.
Worsening Cash Burn TrendRising cash burn and worsening FCF year-over-year compress the company’s runway and force more frequent capital raises. For a biotech undertaking multi-year trials, accelerating cash outflows increase execution risk, potential program delays, and dilution pressure on long-term shareholders.
Tissue Repair Ltd News
TRP FAQ
What was Tissue Repair Ltd’s price range in the past 12 months?
Tissue Repair Ltd lowest share price was AU$0.15 and its highest was AU$0.48 in the past 12 months.
What is Tissue Repair Ltd’s market cap?
Tissue Repair Ltd’s market cap is AU$9.07M.
When is Tissue Repair Ltd’s upcoming earnings report date?
Tissue Repair Ltd’s upcoming earnings report date is Aug 20, 2026 which is in 145 days.
How were Tissue Repair Ltd’s earnings last quarter?
Tissue Repair Ltd released its earnings results on Feb 27, 2026. The company reported -AU$0.036 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.036.
Is Tissue Repair Ltd overvalued?
According to Wall Street analysts Tissue Repair Ltd’s price is currently Overvalued.
Does Tissue Repair Ltd pay dividends?
Tissue Repair Ltd does not currently pay dividends.
What is Tissue Repair Ltd’s EPS estimate?
Tissue Repair Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tissue Repair Ltd have?
Tissue Repair Ltd has 60,464,844 shares outstanding.
What happened to Tissue Repair Ltd’s price movement after its last earnings report?
Tissue Repair Ltd reported an EPS of -AU$0.036 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 9.091%.
Which hedge fund is a major shareholder of Tissue Repair Ltd?
Currently, no hedge funds are holding shares in AU:TRP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tissue Repair Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:TRP Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth AU$8.8K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.23%
12-Months-Change
Fundamentals
Return on Equity
-29.91%
Trailing 12-Months
Asset Growth
-25.56%
Trailing 12-Months
Company Description
Tissue Repair Ltd
Tissue Repair Ltd, a clinical stage biopharmaceutical company, developing advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia. It is developing TR-987 and other dressing/matrices, including Glucoprime technology for the treatment of chronic wounds, burns, and other complex wounds; and TR Pro+ for aftercare of minimally invasive cosmetic procedures, as well as other products for veterinary, new bandage, scaffold products, and other therapeutic indications. The company was incorporated in 2012 and is headquartered in Sydney, Australia.
Technical Analysis
Prescient Therapeutics Limited
―
Regeneus Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Bio-Gene Technology Ltd.
―